Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181127 | 0.94 | — | — | |
| Potassium Ion SCHEMBL344530 | 0.94 | — | — | |
| SCHEMBL3202942 | 0.94 | — | — | |
| SCHEMBL3180441 | 0.94 | — | — | |
| Lithium Ion SCHEMBL3197975 | 0.94 | — | — | |
| SCHEMBL25276832 | 0.94 | MGAM (0.52) | MGAMGAASIMGAM2TSHR | |
| Lithium Ion SCHEMBL15950214 | 0.94 | MGAM (0.52) | MGAMGAASIMGAM2TSHR | |
| Tetramethylammonium Ion SCHEMBL4772224 | 0.89 | MGAM (0.48) | MGAMGAASIMGAM2TSHR | |
| Tetrylammonium SCHEMBL4773294 | 0.83 | MGAM (0.42) | MGAMGAASIMGAM2TSHR | |
| Acetoacetic Acid SCHEMBL29060526 | 0.79 | MGAM (0.71) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115207-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | HEALTH RESEARCH INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3962921-B1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | HEALTH RESEARCH INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12337004-B2 | Coumarin-modified androgens for the treatment of prostate cancer | HEALTH RESEARCH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20220218722-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-07-14 | — | — | US | disclosed |
| WO-2020223174-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | HEALTH RESEARCH, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-10632191-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3124491-B1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS AND VACCINE COMPOSITIONS AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | INFECTIOUS DISEASE RES INST (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180028649-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2018-02-01 | — | — | US | disclosed |
| US-9814772-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170182155-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RES INST (US) | 2017-06-29 | — | — | US | disclosed |
| EP-1781662-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | Pfizer, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007023381-A1 | METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS | PFIZER INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006018725-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-5189043-A | Useful as an inhibitory agent for the biosynthesis of cholesterol | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-23 | — | — | US | disclosed |
| EP-0424929-A1 | Isoquinolone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4870199-A | FROM 3-HYDROXY-4-TRIPHENYLMETHOXYBUTANOIC ACID | SANDOZ PHARM. CORP. (US) | 1989-09-26 | — | — | US | disclosed |
| EP-0244364-A2 | Preparation of olefinic compounds | SANDOZ AG (CH) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115207-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | AR, KLK3, SHBG | MGAM 4819/4885GAA 4814/4885SI 4545/4885 |
| US-12337004-B2 | Coumarin-modified androgens for the treatment of prostate cancer | AR, SHBG, NCOA1 | MGAM 4015/4885GAA 3821/4885SI 4082/4885 |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, GTF3C4, POLRMT | MGAM 3681/4885GAA 320/4885SI 1349/4885 |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | MGAM 3681/4885GAA 320/4885SI 1349/4885 |
| US-10632191-B2 | Synthetic glucopyranosyl lipid adjuvants | B3GAT3, GLA, LGALS8 | MGAM 148/4885GAA 136/4885SI 798/4885 |
| US-20180028649-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | MGAM 148/4885GAA 136/4885SI 798/4885 |
| US-20220218722-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | AR, SHBG, NCOA1 | MGAM 4015/4885GAA 3821/4885SI 4082/4885 |
| US-20170182155-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | MGAM 141/4885GAA 127/4885SI 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.